CollPlant Biotechnologies Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLGN in the last 7 days.
No SEC Form 4 filings for $CLGN in the last 30 days.
See all $CLGN insider activity →CollPlant Biotechnologies Ltd. will issue 989,301 shares at $3.74 each, raising $3.7 million. It will also issue warrants for 1,483,952 shares, exercisable at $3.74 until 2026. The private placement, expected to close by October 14, 2026, involves existing investors and is exempt from registration.
CollPlant reports Ami Sagy's ownership stake decreased to 5.7% due to new share issuances. Sagy confirms no recent transactions. The calculation is based on 2,866,715 outstanding shares post-reverse split, and he may now report under Rule 13d-1(c).
CollPlant Biotechnologies' subsidiary LightSolver filed a provisional patent for its laser-based computing platform, focusing on solving physical and engineering problems. The tech addresses complex equations in heat transfer, diffusion, and fluid-flow. CEO Dr. Ruti Ben-Shlomi highlighted the filing as a key milestone in securing core innovations. CollPlant operates in computing and biotech sectors, including 3D bioprinting and medical aesthetics.
Recent CLGN coverage spans earnings, corporate actions and technology.
Dilutive capital raise may weigh on share price.
The filing is a shareholder-structure update that can affect perceived insider alignment, but it is not an acquisition or disposition by Sagy.
The patent filing introduces a new IP asset for CollPlant, potentially enhancing its valuation as the photonic computing market develops.
The patent filing adds IP protection and may improve long‑term growth expectations for CollPlant.
Earnings miss and modest acquisition suggest short‑term downside pressure.
AlphAI scores every news story that mentions CLGN with an AI model for sentiment and relevance, and aggregates insider trades from CollPlant Biotechnologies Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
CollPlant Biotechnologies Ltd. will issue 989,301 shares at $3.74 each, raising $3.7 million. It will also issue warrants for 1,483,952 shares, exercisable at $3.74 until 2026. The private placement, expected to close by October 14, 2026, involves existing investors and is exempt from registration.
1 min readCollPlant reports Ami Sagy's ownership stake decreased to 5.7% due to new share issuances. Sagy confirms no recent transactions. The calculation is based on 2,866,715 outstanding shares post-reverse split, and he may now report under Rule 13d-1(c).
3 min readCollPlant Biotechnologies' subsidiary LightSolver filed a provisional patent for its laser-based computing platform, focusing on solving physical and engineering problems. The tech addresses complex equations in heat transfer, diffusion, and fluid-flow. CEO Dr. Ruti Ben-Shlomi highlighted the filing as a key milestone in securing core innovations. CollPlant operates in computing and biotech sectors, including 3D bioprinting and medical aesthetics.
1 min readCollPlant's subsidiary, LightSolver, filed a U.S. provisional patent for expanding its photonic computing platform to solve complex scientific and engineering simulations. The invention enables the platform to address partial differential equations, broadening its applications. According to the company, this filing strengthens LightSolver's IP portfolio and supports its strategy for high-performance computing. CollPlant (Nasdaq: CLGN) operates in deep-tech computing and biotechnology.
1 min readCollPlant Biotechnologies reported a GAAP EPS of -$0.87 and revenue of $11.43M, up 116.1% year-over-year. The company reaffirmed its FY 2026 revenue growth guidance of 50% to 100% compared to FY 2025, according to a press release.
1 min readCollplant ADR (CLGN) reported Q3 EPS of -$1.89, beating estimates by $0.56, but revenue of $108K missed expectations of $480K. The stock is up 11.11% in 3 months but down 84.63% in 12 months. InvestingPro rates its financial health as 'weak performance'.
2 min readCollPlant reported H1 2026 revenue of $181,000, down from $2.234M in 2025, with a net loss of $5.823M, wider than the $4.799M loss in 2025. The company warned about liquidity concerns, stating it lacks sufficient funds to operate for 12 months. Post-quarter, CollPlant raised $7.14M from a June offering and warrant exercises.
2 min readCollPlant Biotechnologies Ltd (CLGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Se
2 min readCollPlant (CLGN) reported Q2 2026 financial results, with revenues of $108,000, down from $179,000 in Q2 2025. The company acquired LightSolver, entering the high-performance computing market, and appointed Dr. Ruti Ben Shlomi to its board. CollPlant also continues to focus on regenerative medicine. GAAP net loss for Q2 2026 was $2.7 million, or $1.89 per share.
2 min readCollPlant (CLGN) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing a prior deficiency matter. The company's shares met the criteria for ten consecutive days. CEO Yehiel Tal expressed commitment to advancing the company's technological and commercial roadmap, including developments in photonic computing and biotechnology.
1 min read
